Trials / Not Yet Recruiting
Not Yet RecruitingNCT07414953
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
A Phase Ib Study of the Safety, Efficacy, Pharmacokinetics, and Immunogenicity of HS-10504 Combined Therapy in Advanced Non-small Cell Lung Cancer Patients
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10504 | HS-10504 administered orally every day |
| DRUG | SHR-A2009 | SHR-A2009 administered intravenously |
| DRUG | HS-20122 | HS-20122 administered intravenously |
| DRUG | HS-20117 | HS-20117 administered intravenously |
| DRUG | SHR-1826 | SHR-1826 administered intravenously |
| DRUG | SHR-A2102 | SHR-A2102 administered intravenously |
Timeline
- Start date
- 2026-03-30
- Primary completion
- 2027-04-30
- Completion
- 2028-11-30
- First posted
- 2026-02-17
- Last updated
- 2026-02-17
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07414953. Inclusion in this directory is not an endorsement.